Nagasaki Prefecture To Create Drug Trial Industry
This article was originally published in PharmAsia News
Aiming to establish a drug trial industry, Nagasaki Prefecture will establish a network to link pharmaceutical companies, universities and medical facilities in April. The project will utilize new drug research results and invite major pharmaceutical companies to set up R&D centers inside the prefecture. In Japan, as the associated costs of clinic trials are higher than overseas, connecting pharmaceutical companies to commercialize academic research will help lower research costs and make trials more efficient. Nagasaki Prefecture will also absorb drug trial-related research fees. (Click for more-Japanese language
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.